Loading stock data…
BLRX
$2.86+0.11 (+4.12%)
Market ClosedLast close May 1
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BioLineRx Ltd. in the Healthcare sector is trading at $2.86. The stock is currently near its 52-week low of $2.15, remaining 12.2% below its 200-day moving average. Technical signals show neutral RSI of 66 and bullish MACD crossover, explaining why BLRX maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 66) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.86
Potential Downside
100%
Whystock Fair Value$0.00
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus2 analysts
Mean target$17.50+511.2%
Range$12.00 – $23.00
Fundamentals
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatm...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$10.08M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.48
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-6.46%
Volume
Today's trading volume
12,689
Recent News
BioLine Rx Ltd (BLRX) Full Year 2025 Earnings Call Highlights: Navigating Challenges and ...
Despite a significant revenue drop, BioLine Rx Ltd (BLRX) focuses on innovative treatments and maintains a strong cash position to drive future growth.
BioLine Rx Ltd (BLRX) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...
BioLine Rx Ltd (BLRX) reports reduced net loss and strategic developments in cancer treatment, bolstered by a strong cash position.
H.C. Wainwright Reaffirms Buy on BioLineRx Ltd. (BLRX) After ASCO 2025
BioLineRx Ltd. (NASDAQ:BLRX) is among the best growth stocks to invest in for the next 5 years. H.C. Wainwright reaffirmed its Buy rating on BioLineRx Ltd. (NASDAQ:BLRX) while maintaining a price target of $26.00. This confidence follows the company’s participation in ASCO 2025, where the management presented full data from the pilot phase of its […]
BioLineRx upgraded to Buy from Hold at JonesResearch
JonesResearch upgraded BioLineRx (BLRX) to Buy from Hold with a $12 price target The company announced new pilot phase data from the investigator-initiated Phase II combination trial of motixafortide plus PD-1 inhibitor cemiplimab plus chemo in first line pancreatic cancer where seven of 11 patients responded to therapy and 10 of 11 achieved disease control, the analyst tells investors in a research note. With these results, the firm believes BioLineRx will have additional opportunities to eithe
Why Is Nano-Cap BioLineRx Stock Surging On Friday?
BioLineRx Ltd’s (NASDAQ:BLRX) poster, which includes new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination trial, will be presented at the 2025 American Society of Clinical Oncology Annual Meeting. The CheMo4METPANC trial is evaluating motixafortide, cemiplimab, and standard-of-care chemotherapies gemcitabine and nab-paclitaxel, versus gemcitabine and nab-paclitaxel alone, in first-line pancreatic cancer (PDAC). Updated results from